

Jingwen Wang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6922551/jingwen-wang-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

124
citations

5
h-index

11
g-index

20
ext. papers

186
ext. citations

4.4
avg, IF

1.13
L-index

#	Paper	IF	Citations
16	A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3K Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China. <i>Blood</i> , 2021 , 138, 3536-3536	2.2	
15	Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 863-869	4.9	0
14	The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	3
13	Outcomes of patients treated with SVILE P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study. <i>Cancer Biology and Medicine</i> , 2020 , 17, 795-804	5.2	0
12	Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia. <i>Aging</i> , 2020 , 12, 25337-25355	5.6	1
11	Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2962-2968 ¹⁹		
10	SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia Research</i> , 2020 , 96, 106422	2.7	0
9	Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 337-343	1.9	5
8	Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial. <i>Blood</i> , 2019 , 134, 4036-4036	2.2	3
7	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. <i>Science China Life Sciences</i> , 2018 , 61, 924-933	8.5	1
6	Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. <i>International Journal of Hematology</i> , 2018 , 107, 98-104	2.3	9
5	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018 , 109, 3943-3952	6.9	10
4	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 69	22.4	85
3	Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016 , 128, 5536-5536	2.2	1
2	Primary Breast Diffuse Large B Cell Lymphoma in the Rituximab Era: Outcomes of a Multicenter Retrospective Study By the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society(LLC-CGOS). <i>Blood</i> , 2016 , 128, 4228-4228	2.2	1
1	Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI. <i>Acta Radiologica</i> , 2016 , 57, 1490-1496 ⁵		